Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.75 USD
+0.07 (4.17%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AADI 1.75 +0.07(4.17%)
Will AADI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AADI
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Other News for AADI
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience presents new subgroup analysis in advanced malignant PEComa
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)